Foss, F., Horwitz, S., Pro, B., Prince, H. M., Sokol, L., Balser, B., . . . Coiffier, B. (2016). Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: Prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol.
Citação norma ChicagoFoss, Francine, Steven Horwitz, Barbara Pro, H. Miles Prince, Lubomir Sokol, Barbara Balser, Julie Wolfson, and Bertrand Coiffier. "Romidepsin for the Treatment of Relapsed/refractory Peripheral T Cell Lymphoma: Prolonged Stable Disease Provides Clinical Benefits for Patients in the Pivotal Trial." J Hematol Oncol 2016.
MLA citiranjeFoss, Francine, et al. "Romidepsin for the Treatment of Relapsed/refractory Peripheral T Cell Lymphoma: Prolonged Stable Disease Provides Clinical Benefits for Patients in the Pivotal Trial." J Hematol Oncol 2016.